StockData
Hims & Hers Health, Inc. logo

Hims & Hers Health, Inc. (HIMS) stock

HIMSNYSEServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30187% above fair value
$18.56−1.17 (-5.93%)

Close on Nov 16, 2026Market cap $4.33BP/E –Yield –

Earnings

Hims & Hers Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 22, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$890.40M
+48.6% on a year earlier
EPS, Q3 FY2026
-$0.14
$0.06 a year earlier
Latest guidance
Issued
Nov 9, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Hims & Hers Health's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 22, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026after the close$890.40M+48.6%-$0.14Release
Q2 FY2026ended Jun 30, 2026Aug 10, 2026after the close$753.20M+38.3%–Release
Q1 FY2026ended Mar 31, 2026May 11, 2026after the close$608.10M+3.8%-$0.40Release
Q4 FY2025ended Dec 31, 2025Feb 23, 2026after the close$617.80M+28.4%$0.08Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025after the close$599.00M+49.2%$0.06Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025after the close$544.80M+72.6%$0.17Release
Q1 FY2025ended Mar 31, 2025May 5, 2025after the close$586.00M+110.6%$0.20Release
Q4 FY2024ended Dec 31, 2024Feb 24, 2025after the close$481.10M+95.1%$0.11Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024after the close$401.60M+77.2%$0.32Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024after the close$315.60M+51.8%$0.06Release
Q1 FY2024ended Mar 31, 2024May 6, 2024after the close$278.20M+45.8%$0.05Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Hims & Hers Health's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueGAAPQ4 FY2026$875.00M – $895.00M–NewNov 9, 2026
Adjusted EBITDAnon-GAAPQ4 FY2026$70.00M – $90.00M–NewNov 9, 2026
Adjusted EBITDA marginnon-GAAPQ4 FY20268% – 10%–NewNov 9, 2026
RevenueGAAPFY2026$3.13B – $3.15B–NewNov 9, 2026
RevenueFY2026$3.10B – $3.30B$2.80B – $3.00BRaisedAug 10, 2026
Adjusted EBITDAnon-GAAPFY2026$257.00M – $277.00M–NewNov 9, 2026
Adjusted EBITDAnon-GAAPFY2026$275.00M – $325.00M$275.00M – $350.00MLoweredAug 10, 2026
Adjusted EBITDA marginnon-GAAPFY20268% – 9%–NewNov 9, 2026
Adjusted EBITDA marginnon-GAAPFY202610% – 12%11% – 13%LoweredMay 11, 2026
RevenueFY2030$6.50B–NewMay 5, 2025
Adjusted EBITDAnon-GAAPFY2030$1.30B–NewMay 5, 2025

Guidance vs results

The last range Hims & Hers Health gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026Revenue$880.00M – $900.00M$890.40MWithin range
Q2 FY2026Revenue$680.00M – $700.00M$753.20MAbove range
Q1 FY2026Revenue$600.00M – $625.00M$608.10MWithin range
FY2025Revenue$2.34B – $2.36B$2.35BΣ4QWithin range
Q4 FY2025Revenue$605.00M – $625.00M$617.80MWithin range
Q3 FY2025Revenue$570.00M – $590.00M$599.00MAbove range
Q2 FY2025Revenue$530.00M – $550.00M$544.80MWithin range
Q1 FY2025Revenue$520.00M – $540.00M$586.00MAbove range
Q4 FY2024Revenue$465.00M – $470.00M$481.10MAbove range
Q3 FY2024Revenue$375.00M – $380.00M$401.60MAbove range
Q2 FY2024Revenue$292.00M – $297.00M$315.60MAbove range
Q1 FY2024Revenue$267.00M – $272.00M$278.20MAbove range

Guidance history

Every forecast Hims & Hers Health put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 9, 2026Adjusted EBITDAFY2026$257.00M – $277.00MNew
Nov 9, 2026Adjusted EBITDAQ4 FY2026$70.00M – $90.00MNew
Nov 9, 2026Adjusted EBITDA marginQ4 FY20268% – 10%New
Nov 9, 2026Adjusted EBITDA marginFY20268% – 9%New
Nov 9, 2026RevenueFY2026$3.13B – $3.15BNew
Nov 9, 2026RevenueQ4 FY2026$875.00M – $895.00MNew
Aug 10, 2026Adjusted EBITDAFY2026$275.00M – $325.00MLowered
Aug 10, 2026Adjusted EBITDAQ3 FY2026$75.00M – $95.00MNew
Aug 10, 2026RevenueQ3 FY2026$880.00M – $900.00MNew
Aug 10, 2026RevenueFY2026$3.10B – $3.30BRaised
May 11, 2026Adjusted EBITDAQ2 FY2026$35.00M – $55.00MNew
May 11, 2026Adjusted EBITDAFY2026$275.00M – $350.00MLowered
May 11, 2026Adjusted EBITDA marginFY202610% – 12%Lowered
May 11, 2026Adjusted EBITDA marginQ2 FY20265% – 8%New
May 11, 2026RevenueFY2026$2.80B – $3.00BRaised
May 11, 2026RevenueQ2 FY2026$680.00M – $700.00MNew
Feb 23, 2026Adjusted EBITDAQ1 FY2026$35.00M – $55.00MNew
Feb 23, 2026Adjusted EBITDAFY2026$300.00M – $375.00MNew
Feb 23, 2026Adjusted EBITDA marginFY202611% – 13%New
Feb 23, 2026Adjusted EBITDA marginQ1 FY20266% – 9%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Hims & Hers Health filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. News
  5. News
  6. Results
  7. Update
  8. Results
  9. Results
  10. Update
  11. Results
  12. Results
  13. Results
  14. Results
  15. News

See a number that looks wrong?